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Objectives The goal of this study was to compare the long-term clinical outcome between everolimus-
eluting stent (EES) and sirolimus-eluting stent (SES) in patients with acute coronary syndromes (ACS).
Background EES have not been directly compared with SES in ACS patients to date.
Methods Between 2004 and 2009, 1,746 consecutive ACS patients (ST-segment elevation ACS [STE-
ACS]: 33.5%; non–ST-segment elevation ACS [NSTE-ACS]: 66.5%) were treated with EES (n  903) or
ES (n  843). Using propensity score matching, clinical outcome was compared among 705
atched pairs of ACS patients treated with EES and SES.
esults Through 3 years, the primary endpoint—the composite of death, myocardial infarction (MI),
nd target vessel revascularization (TVR)—occurred in 13.8% of EES- and 17.7% of SES-treated ACS
atients (hazard ratio [HR]: 0.72, 95% conﬁdence interval [CI]: 0.54 to 0.95, p  0.02). The difference
n favor of EES was driven by a lower risk of TVR (5.7% vs. 8.8%, HR: 0.65, 95% CI: 0.43 to 0.98, p 
.04) and a trend toward a lower risk of MI (2.1% vs. 3.3%, HR: 0.56, 95% CI: 0.29 to 1.12, p  0.10).
he risk of death (7.2% vs. 8.8%, HR: 0.75, 95% CI: 0.50 to 1.10, p  0.14) showed no difference be-
tween EES and SES. The treatment effect in favor of EES for the primary endpoint was similar for
patients with STE-ACS (16.4% vs. 18.5%, HR: 0.80, 95% CI: 0.50 to 1.27) and NSTE-ACS (12.4% vs.
17.3%; HR: 0.67, 95% CI: 0.47 to 0.96; pfor interaction  0.56) and across major subgroups. Deﬁnite
(0.4% vs. 1.8%, p  0.03), and deﬁnite or probable stent thrombosis (3.4% vs. 6.1%, p  0.02) were
less frequent among EES- than SES-treated ACS patients.
Conclusions Among patients with ACS, the unrestricted use of EES is associated with improved
clinical outcome compared with SES during long-term follow-up to 3 years. Notably, the risk of
stent thrombosis was lower among EES-treated ACS patients. (J Am Coll Cardiol Intv 2012;5:
145–54) © 2012 by the American College of Cardiology Foundation
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146Acute coronary syndromes (ACS) constitute the most
frequent indication for percutaneous coronary intervention
(PCI) in contemporary practice because of improved clinical
outcome compared with a conservative strategy (1). This
clinical entity includes a wide spectrum of presentations,
ranging from unstable angina over non–ST-segment eleva-
tion (NSTE) to ST-segment elevation acute coronary syn-
drome (STE) ACS, sharing a common pathophysiological
origin related to coronary plaque erosion or rupture with
variable degrees of lumen obstruction and thrombosis (2,3).
The use of sirolimus-eluting stents (SES) has been shown to
be as safe as the use of bare-metal stents in several studies
with the inclusion of ACS patients (4–9). Nevertheless, the
thrombogenic milieu coupled with evidence for delayed
arterial healing as well as neoatherosclerosis following drug-
eluting stent (DES) implanta-
tion in plaques of patients with
ACS have led to concerns with
respect to the long-term safety
of these devices in the setting of
ACS (10–12). Newer-generation
DES, such as the everolimus-
eluting stent (EES), have been de-
veloped to improve upon the safety
and efficacy profile of early-
generation devices and are widely
used in contemporary practice
(13,14). However, EES have not
been directly compared with SES in
ACS patients to date. We recently
reported improved clinical outcome
with the unrestricted use of EES
compared with SES in a large pro-
pensity score–matched cohort fol-
lowed up to 3 years as part of the
LESSON (Long-term compari-
son of Everolimus-eluting and
Sirolimus-eluting Stents for coro-
nary revascularizatiON) study (15).
The aim of the present study was to investigate the long-term
safety and efficacy of EES and SES among patients with ACS
who are at increased risk of recurrent adverse events, including
stent thrombosis (ST).
Methods
Study population. Patients undergoing implantation of
ES at Bern University Hospital, Bern, Switzerland, were
rospectively entered into the Bern DES registry. A total of
,746 patients presenting with ACS were treated with at
east 1 SES (Cypher, Cordis, Miami Lakes, Florida) (n 
43) between May 2004 and January 2006 or at least 1 EES
XIENCE V, Abbott Vascular, Santa Clara, California, or
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
CI  confidence interval
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
HR  hazard ratio
MI  myocardial infarction
NSTE  non–ST-segment
elevation
PCI  percutaneous
coronary intervention
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
STE  ST-segment elevation
TLR  target lesion
revascularization
TVR  target vessel
revascularizationROMUS, Boston Scientific, Natick, Massachusetts) (n  p03) between November 2006 and March 2009. Patients
reated with SES before the initiation of the SIRTAX
Sirolimus-Eluting Stent Compared With Paclitaxel-
luting Stent for Coronary Revascularization) trial were not
ligible because a standardized, long-term prescription of
lopidogrel of 12 months was implemented only in view of
he initiation of this trial. Patients treated with SES
ncluded into the SIRTAX trial (16) were not eligible in
iew of mandated follow-up angiography. The study com-
lied with the declaration of Helsinki and was approved by
ur institutional ethics committee. All patients gave their
ritten informed consent to be followed prospectively.
Data collection. All patients were followed up for major
dverse cardiac events using patient-administered postal
uestionnaires, including questions on rehospitalization and
ajor adverse cardiac events, which were sent out repeti-
ively during prespecified time windows. The last follow-up
as performed between July 2007 and June 2008 in patients
ho underwent implantation of SES and between June
009 and March 2010 in patients with EES. In case of a
issing response to the postal questionnaire within 4 weeks,
second questionnaire was sent out, which was followed by
elephone calls in case of no reply after an additional 2 weeks
f no response. If all 3 contact attempts remained unsuc-
essful, the general practitioner was contacted in order to
btain more information whenever possible, and—as a last
ption—an attempt to contact the patient’s relatives was
ade. Vital status was ascertained from hospital records and
unicipal civil registries. For patients with a suspected
vent, relevant medical records, discharge letters, and coro-
ary angiography documentation were systematically col-
ected. All suspected events were independently adjudicated
y a clinical event committee blinded to the type of stent
mplanted (15). Baseline clinical and procedural character-
stics and all follow-up data were entered into a dedicated
atabase, held at an academic clinical trials unit (CTU Bern,
ern University Hospital, Bern, Switzerland) responsible
or central data audits and maintenance of the database.
Procedures. EES were available in diameters from 2.25 to
.0 mm and in lengths from 8 to 28 mm; SES were available
n diameters from 2.25 to 3.5 mm and in lengths from 8 to
3 mm. The treatment guidelines, including peri- and
ost-procedural medication regimen, were performed ac-
ording to current practice guidelines and did not change
etween the inclusion of the first patient into the SES
ohort and inclusion of the last patient into the EES cohort.
uring the study period, PCI and the use of stents was
uided by angiography and only in limited cases by intra-
ascular ultrasound. Pre-dilation was performed at the
iscretion of the operator with a balloon-to-artery ratio
iming at 1:1. Stents were implanted with the aim to cover
he entire lesion. In case of stent overlap, the operator aimed
o achieve an overlapping margin of at least 2 mm. High-
ressure stent implantation was used in case of incomplete
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147stent expansion or stent overlap. All patients, irrespective of
stent type, received a loading dose of clopidogrel 300 mg to
600 mg during or immediately after the procedure and were
prescribed aspirin once daily lifelong and clopidogrel for 12
months. The use of glycoprotein IIb/IIIa antagonists was
left to the discretion of the operator. Creatine kinase (CK),
creatine kinase-myocardial band (CK-MB), and troponin
were routinely assessed at baseline and 12 to 24 h after PCI,
as was a 12-lead electrocardiogram. Biomarkers were sam-
pled every 6 to 8 h in patients with signs of ischemia until
identification of peak levels.
Deﬁnitions. The primary endpoint was the composite of
eath, myocardial infarction (MI), and target vessel
evascularization (TVR) up to a maximum follow-up of 3
ears. Secondary endpoints were the single components
f the primary endpoint, as well as cardiac death, target
esion revascularization (TLR), and definite and definite
r probable ST according to Academic Research Con-
ortium criteria (17).
The definition of cardiac death included any death due to
n immediate cardiac cause, procedure-related death, un-
itnessed death, and death due to an unknown cause.
-wave MI diagnosis required new pathological Q waves in
or more contiguous electrocardiogram leads. In the
bsence of pathological Q waves, the diagnosis of MI was
ased on a CK elevation to more than twice the upper limit
f normal and an elevation of CK-MB or troponin to more
han 3 times the upper limit of normal. TVR was defined as
ny repeat revascularization of any segment within the
ntire major coronary vessel proximal and distal to a target
esion. TLR was defined as revascularization for a stenosis
ithin the stent or within the 5-mm borders proximal and
istal to the stent. ACS definition was based on the
resence of typical clinical symptoms associated with elec-
rocardiographic changes of ischemia and/or elevated car-
iac troponin (18). STE-ACS diagnosis was based on the
vidence of persistent (20 min) STE1 mm in 2 or more
ontiguous leads (19). NSTE-ACS diagnosis was based on
he presence of typical clinical symptoms associated with
schemic electrocardiographic changes, without persistent
T-segment elevation. Among NSTE-ACS, unstable an-
ina and NSTEMI were discriminated according to the
vidence of elevated cardiac troponin (18).
Statistical analysis. We compared baseline characteristics
etween ACS patients treated with EES and SES using
chi-square test for categorical variables and an unpaired
test for continuous variables. We then used propensity
core matching to account for differences in baseline char-
cteristics between groups. The propensity scores for receiv-
ng EES were estimated using a probit model, including
ge, sex, and pre-treatment variables associated with stent
election in the multivariable model at p  0.10 as inde-
endent variables (arterial hypertension, current smoking,
linical manifestation of coronary artery disease at baseline,nd left ventricular ejection fraction50%). The propensity
core is the probability that a patient would have been
reated with EES given the patient’s observed pre-treatment
haracteristics (20). Observations matched on the basis of
he propensity scores using a conservative caliper are likely
o have comparable distributions of baseline characteristics.
o determine whether this assumption of balanced baseline
haracteristics was satisfied, we used standard comparison
ests (unpaired t test and Pearson chi-square test). To match
atients, we used an automated matching procedure in the
oftware package that randomly selected a patient treated
ith EES and a randomly selected patient treated with SES
rom the pool of potential patients with propensity scores
ithin a caliper of 0.05 on the propensity score within
TE-ACS and NSTE-ACS separately. Successfully
atched pairs were removed and the procedure repeated
ntil all patients treated with EES were matched to 1
omparator or until no further patients with SES were
vailable within the caliper. For each pair, we ensured equal
ollow-up times by discarding observation time in the
atient treated with SES, which extended beyond the
ollow-up duration of the corresponding patient treated
ith EES. We used Cox proportional hazards models that
ccounted for the 1:1 matching to calculate hazard ratios
HRs) of all primary and secondary outcomes comparing
he 2 stent types over the entire follow-up time up to 3 years
primary time point), and up to 30 days and 1 year
secondary time points) for patients with ACS at baseline;
nd after stratification for ACS type, we did the same for
TE-ACS and NSTE-ACS. As it relates to ST, we
erformed landmark analyses according to time points
pecified in Academic Research Consortium definitions
17). All p values and 95% confidence intervals (CIs) are
-sided.
esults
A total of 1,746 patients (98.7%) completed the last
follow-up as planned on all clinical outcomes, with 843
patients receiving EES (98.7%), and 903 patients receiving
SES (98.7%). The median follow-up duration among sur-
viving patients completing the last follow-up was 1.7 years
in patients treated with EES (range: 1.1 to 2.4 years) and
2.8 years in patients treated with SES (range: 2.5 to 3.2
years) with an accumulated 1,557 and 2,223 patient-years,
respectively. Of 1,746 patients with ACS, 585 patients
(33.5%) presented with STE-ACS and 1,161 patients
(66.5%) with NSTE-ACS. Table 1 (left) summarizes base-
line clinical characteristics before propensity score match-
ing. ACS patients treated with EES were older, more
frequently hypertensive, smoking, presenting with cardio-
genic shock and with a lower left ventricular ejection
fraction, and differed in terms of clinical indication. Using
propensity score matching, 705 patients treated with EES
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148were matched with 705 patients treated with SES. The
median follow-up duration was 1.3 years in both groups
(range: 1.0 to 2.2 years), with an accumulated 1,192 and 1,161
patient-years for EES- and SES-treated patients, respectively.
After matching, baseline characteristics were comparable be-
tween groups (Table 1, right). A comparison of procedural
characteristics and medication at discharge between EES- and
SES-treated patients after propensity score matching is re-
ported in Table 2. Overall, EES-treated patients appeared
more complex as indicated by a higher prevalence of multives-
sel disease, and a higher number of lesions and vessels treated
per patient with corresponding differences in the number of
stents. SES-treated patients were more frequently discharged
with statin therapy than EES-treated patients; as it relates to
other medications, no difference was observed between the 2
stent groups.
Clinical outcomes for the overall ACS population strat-
ified according to stent type are summarized in Table 3 at 30
days, 1 year, and up to 3 years. Among patients with ACS,
the primary endpoint occurred less frequently among EES-
than SES-treated patients (13.8% vs. 17.7%, HR: 0.72, 95%
CI: 0.54 to 0.95, p  0.02) (Fig. 1). The difference in favor
of EES was driven by a lower rate of TVR (5.7% vs. 8.8%,
HR: 0.65, 95% CI: 0.43 to 0.98, p  0.04) and a trend
toward a lower rate of MI (2.1% vs. 3.3%, HR: 0.56, 95%
CI: 0.29 to 1.12, p  0.10), whereas no difference was
observed in terms of death (7.2% vs. 8.8%, HR: 0.75, 95%
CI: 0.50 to 1.10, p  0.14) (Fig. 2). Compared with SES,
ACS patients treated with EES had a lower risk of definite
ST (0.4% vs. 1.8%, HR: 0.25, 95% CI: 0.07 to 0.89, p 
Table 1. Baseline Characteristics Before and After Propensity Score Match
Before Propensi
EES (n  903) SE
Age, yrs 64.4 12.4 6
Male 677 (75.0)
Body mass index, kg/m2 27.2 5.2 2
Diabetes mellitus 140 (15.5)
Insulin-requiring diabetes 46 (5.1)
Hypertension 487 (53.9)
Hypercholesterolemia 405 (44.9)
Current smoking 300 (33.2)
Impaired renal function 25 (2.8)
Type of indication
Unstable angina 115 (12.7)
Non–ST-segment elevation myocardial infarction 527 (58.4)
ST-segment elevation acute coronary syndrome 261 (28.9)
Cardiogenic shock 35 (3.9)
Left ventricular ejection fraction 50% 411 (45.5)
Values are mean SD or n (%).
EES everolimus-eluting stent(s); MImyocardial infarction; SES sirolimus-eluting stent(s).0.032), and definite or probable ST (3.4% vs. 6.1%, HR:0.55, 95% CI: 0.33 to 0.91, p  0.02) up to 3 years (Table 4).
Differences emerged early and continued to diverge during
long-term follow-up (Fig. 3).
A signal in favor of treatment with EES was observed
among all major subgroups, including age, sex, obesity,
diabetes mellitus, hypertension, hypercholesterolemia, and
left ventricular ejection fraction (Fig. 4). However, most
confidence intervals crossed the line of unity—mainly be-
cause of the limited number of patients per group—and
therefore allow no definite conclusion. An analysis of
outcomes according to type of ACS (STE vs. NSTE) is
summarized in Table 5. Although differences between EES
and SES failed to reach conventional levels of significance
among STE-ACS patients for the primary endpoint (16.4%
vs. 18.5%, HR: 0.80, 95% CI: 0.50 to 1.27, p  0.35),
confidence intervals overlapped widely, and formal tests of
interaction showed no difference between STE-ACS and
NSTE-ACS (12.4% vs. 17.3%, HR: 0.67, 95% CI: 0.47 to
0.96, p  0.03, pfor interaction  0.56).
Discussion
In the present observational propensity score–matched
study with long-term follow-up through 3 years, the use of
EES compared with SES among ACS patients was associ-
ated with:
1. A lower risk of the primary endpoint—a composite of
death, MI, and TVR—that was driven by a lower risk
of TVR and a trend toward a lower risk of MI.
re Matching After Propensity Score Matching
843) p Value EES (n  705) SES (n  705) p Value
11.9 0.0001 61.5 11.8 62.4 11.8 0.15
9.1) 0.04 567 (80.4) 540 (76.6) 0.48
4.3 0.83 27.2 4.3 27.34.3 0.48
5.3) 0.91 98 (13.9) 112 (15.9) 0.30
.6) 0.66 34 (4.8) 36 (5.1) 0.79
7.2) 0.005 330 (46.8) 354 (50.2) 0.20
3.5) 0.58 314 (44.5) 307 (43.6) 0.71
9.5) 0.006 277 (39.3) 260 (36.9) 0.35
.5) 0.72 17 (2.4) 20 (2.8) 0.62
0.0001 0.07
.6) 41 (5.8) 63 (8.9)
4.0) 426 (60.4) 404 (57.4)
8.4) 238 (33.8) 238 (33.8)
.8) 0.009 28 (3.9) 15 (2.1) 0.06
5.7) 0.0001 358 (50.8) 348 (49.4) 0.59ing
ty Sco
S (n 
1.5
667 (7
7.3
129 (1
39 (4
398 (4
367 (4
333 (3
21 (2
64 (7
455 (5
324 (3
15 (1
470 (52. A lower risk of definite and definite or probable ST.
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149The use of early-generation DES in patients with ACS
has been a matter of debate, and ACS still constitutes an
off-label indication for the use of these devices according to
the U.S. Food and Drug Administration. The risk of early
ST is increased in ACS patients compared with stable
patients, with the highest risk being observed among STE-
ACS patients. Moreover, lesions with plaque rupture and
thrombus formation as frequently observed in the setting of
ACS (3) have been associated with delayed arterial healing
and neoatherosclerosis in response to DES implantation in
autopsy studies (10,12), raising safety concerns with respect
to the risk of late ST (11). Notwithstanding, early-generation
DES have been shown to reduce the risk of repeat revas-
cularization as compared with bare-metal stents in ACS
Table 2. Procedural Characteristics and Medications at Discharge After
Propensity Score Matching
EES
(n  705)
SES
(n  705) p Value
Procedural characteristics
Multivessel treatment 147 (20.9) 97 (13.8) 0.0001
Number of vessels treated per patient 1.2 0.4 1.1 0.4 0.001
Number of lesions treated per patient 1.8 1.0 1.5 0.7 0.0001
1 lesion 377 (59.0) 455 (64.5)
2 lesions 194 (27.5) 182 (25.8)
3 lesions 87 (12.3) 59 (8.4)
4 lesions 47 (6.7) 8 (1.1)
Target vessel
Left main 19 (2.7) 11 (1.6) 0.20
Left anterior descending 340 (48.2) 352 (49.9) 0.51
Left circumﬂex 208 (29.5) 152 (21.6) 0.001
Right coronary artery 259 (36.7) 256 (36.3) 0.88
Arterial bypass graft 0 (0) 0 (0)
Saphenous vein graft 19 (2.7) 15 (2.1) 0.49
Number of stents per patient 2.0 1.1 1.8 1.0 0.0001
Average stent diameter, mm 3.0 0.4 2.9 0.3 0.06
Total stent length per patient, mm 32.7 19.1 33.4 18.8 0.47
Glycoprotein IIb/IIIa antagonist 322 (45.7) 315 (44.7) 0.71
Medications at discharge
Aspirin 686 (97.3) 679 (96.3) 0.36
Clopidogrel 686 (97.3) 681 (96.6) 0.53
Oral anticoagulation 9 (1.3) 10 (1.4) 0.82
Beta-blocker 491 (69.7) 463 (66.0) 0.14
ACE inhibitor 449 (64.8) 449 (63.7) 0.66
AT II inhibitor 69 (9.8) 88 (12.5) 0.10
Calcium antagonist 27 (3.8) 35 (5.0) 0.29
Statin 581 (82.4) 617 (87.9) 0.004
Oral antidiabetic agents 45 (6.4) 50 (7.1) 0.58
Insulin 34 (4.8) 36 (5.1) 0.79
Diuretics 120 (17.0) 125 (17.7) 0.21
Proton pump inhibitor 120 (17.0) 125 (17.8) 0.70
Values are n (%) or mean SD.
ACE angiotensin-converting enzyme; AT II angiotensin II; other abbreviations as in Table 1.patients without overt differences in rates of death, MI, or sST within 2 years of the index PCI (6). In addition, SES
has been shown to provide sustained efficacy and safety
among patients with acute MI in several studies with
long-term follow-up (8,9,21). More recently, newer-
generation EES have been introduced with the aim to
improve upon the safety profile of early-generation devices.
EES have been shown superior to paclitaxel-eluting stents
in large-scale clinical trials powered for angiographic
(22,23) as well as clinical outcomes (13,14). Evidence is less
well established for the comparison of EES with SES. The
SORT-OUT IV (Scandinavian Organization for Random-
ized Trials with Clinical Outcome SORT-OUT IV) trial (n 
2,774) reported noninferiority of EES compared with SES
in terms of major adverse cardiac events at 9 months in an
all-comers population (4.9% vs. 5.2%, pnoninferiority  0.01).
n BASKET PROVE (Basel Stent Cost-Effectiveness Trial–
rospective Validation Examination), SES and EES were
ssociated with similar clinical outcomes at 2 years with
espect to the composite of death, MI, and TVR (HR: 1.05,
5% CI: 0.74 to 1.51, p  0.90) among 2,314 patients with
arge vessels (24). Although a formal subgroup analysis of
he ISAR-TEST 4 (Intracoronary Stenting and Angio-
raphic Results: Test Efficacy of 3 Limus-Eluting Stents-4)
tudy showed no significant difference between EES and
ES in terms of target lesion failure among 1,304 stable
atients (relative risk: 0.87, 95% CI: 0.68 to 1.11, p 0.26),
trend toward a lower risk of TLR (relative risk: 0.80, 95%
I: 0.59 to 1.08, p  0.15) and a significantly lower rate of
inary restenosis (12.7% vs. 16.9%, p  0.03) favoring EES
ere observed at 3 years (25). Similarly, we recently re-
orted a trend toward a lower risk of the composite of death,
I, and TVR in a propensity score–matched comparison of
he unrestricted use of EES with SES (HR: 0.83, 95% CI:
.68 to 1.00, p  0.056) during long-term follow-up
hrough 3 years (15). However, no dedicated study has
ompared the outcomes of EES with SES in the specific
etting of ACS to date.
In the present study, the risk of TVR was 35% lower with
ES compared with SES, mainly related to a lower risk of
LR suggesting improved efficacy with the newer-
eneration DES during long-term follow-up in ACS pa-
ients. Angiographic and intravascular ultrasound studies
ndicate that the suppression of neointimal hyperplasia is at
east as potent with EES compared with SES and possibly
ore homogenous (13,22,23,26–28). In addition, differ-
nces in strut thickness (81 m vs. 140 m) and polymer
coating (7.6 m vs. 12.6 m) may portend improved
utcome. Thin-strut stents have been shown more effective
han thick-strut stents, and a thin-strut bare-metal stent
esulted in similar rates of restenosis as a thick-strut SES in
atients with large vessels (29).
The absolute difference in favor of EES diminishedomewhat over time, which was related to an increase in
ion reva
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150overall event rates in both groups, and reduced the signifi-
cance of differences between 1 and 3 years of follow-up.
We recorded a 45% lower risk of definite or probable ST
with the use of EES among ACS patients. Moreover, no
cases of definite and definite or probable ST were observed
during the late (30 days) and very late (1 year) time
periods. This finding is of importance because the unre-
stricted use of early-generation DES was associated with an
ongoing risk of very late ST during long-term follow-up and
Table 3. Clinical Outcomes Up to 3 Years in Patients With ACS
30 Days
EES
(n  705)
SES
(n  705) HR (95% CI)
p
Value
EES
(n  70
Death 21 (3.0) 34 (4.8) 0.59 (0.34–1.02) 0.06 40 (5.7
Cardiac death 21 (3.0) 29 (4.1) 0.69 (0.39–1.22) 0.20 32 (4.5
MI 6 (0.9) 14 (2.0) 0.36 (0.13–0.99) 0.048 11 (1.6
TLR 6 (0.9) 12 (1.7) 0.50 (0.19–1.33) 0.17 19 (2.7
TVR 7 (1.0) 16 (2.3) 0.38 (0.15–0.96) 0.04 26 (3.7
Death or MI 26 (3.7) 47 (6.7) 0.51 (0.31–0.83) 0.007 50 (7.1
Cardiac death or MI 26 (3.7) 42 (6.0) 0.57 (0.35–0.94) 0.03 42 (6.0
Cardiac death, MI, or TLR 30 (4.3) 47 (6.7) 0.60 (0.37–0.95) 0.03 57 (8.1
Cardiac death, MI, or TVR 30 (4.3) 50 (7.1) 0.56 (0.35–0.89) 0.01 62 (8.8
Death, MI, or TLR 30 (4.3) 52 (7.4) 0.54 (0.34–0.85) 0.008 65 (9.2
Death, MI, or TVR 30 (4.3) 55 (7.8) 0.51 (0.32–0.80) 0.004 70 (9.9
Values are n (%).
ACS acute coronary syndrome(s); CI confidence interval; HR hazard ratio; TLR target les
Figure 1. Primary Endpoint Through 3 Years
Cumulative incidence of the primary endpoint through 3 years according to st
EES  everolimus-eluting stent(s); MI  myocardial infarction; PCI  percutan
revascularization.stirred a debate regarding the need of prolonged dual
antiplatelet therapy. It is tempting to hypothesize that the
trend toward a lower risk of MI in favor of EES was directly
related to the lower rate of ST. The clinical finding of a
lower rate of ST is supported by experimental data in
comparative studies showing more rapid re-endothelialization
with EES compared with SES and paclitaxel-eluting stents
(30). The mechanisms underlying a reduced risk of ST with
EES remain speculative, but may be related to factors
1 Year 3 Years
SES
 705) HR (95% CI)
p
Value
EES
(n  705)
SES
(n  705) HR (95% CI)
p
Value
50 (7.1) 0.75 (0.49–1.16) 0.19 51 (7.2) 62 (8.8) 0.75 (0.50–1.10) 0.14
40 (5.7) 0.74 (0.46–1.20) 0.23 39 (5.5) 45 (6.4) 0.77 (0.49–1.21) 0.25
20 (2.8) 0.45 (0.20–0.99) 0.047 15 (2.1) 23 (3.3) 0.56 (0.29–1.12) 0.10
33 (4.7) 0.59 (0.34–1.05) 0.07 26 (3.7) 41 (5.8) 0.63 (0.38–1.03) 0.07
53 (7.5) 0.48 (0.30–0.78) 0.003 40 (5.7) 62 (8.8) 0.65 (0.43–0.98) 0.04
65 (9.2) 0.70 (0.48–1.03) 0.07 65 (9.2) 80 (11.4) 0.73 (0.52–1.03) 0.07
56 (7.9) 0.67 (0.44–1.02) 0.06 53 (7.5) 64 (9.1) 0.73 (0.49–1.07) 0.10
77 (10.9) 0.68 (0.48–0.97) 0.03 74 (10.5) 92 (13.1) 0.73 (0.53–1.00) 0.05
94 (13.3) 0.61 (0.44–0.85) 0.004 85 (12.1) 109 (15.5) 0.72 (0.53–0.98) 0.04
86 (12.2) 0.70 (0.50–0.98) 0.04 86 (12.2) 108 (15.3) 0.73 (0.54–0.98) 0.04
03 (14.6) 0.63 (0.46–0.87) 0.005 97 (13.8) 125 (17.7) 0.72 (0.54–0.95) 0.02
scularization; TVR target vessel revascularization; other abbreviations as in Table 1.
pe. p Values were calculated according to Cox proportional hazards models.
oronary intervention; SES  sirolimus-eluting stent(s); TVR  target vessel5) (n
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151including reduced strut thickness resulting in more rapid
and complete endothelialization, a biocompatible polymer
less prone to hypersensitivity reactions, and a lower dose of
the antiproliferative drug (15,31).
Our results suggest that the benefit associated using EES
as observed in the overall ACS population was similar
among STE-ACS and NSTE-ACS patients. Although the
Figure 2. Clinical Outcomes
Cumulative event rates of death, MI, TVR, the composite of death and MI, and
3-year follow-up. p Values were calculated according to Cox proportional haza
Table 4. ST Up to 3 Years in Patients With ACS
EES
(n  705)
SES
(n  705) HR (95% CI)
p
Value
Deﬁnite ST
Early 3 (0.4) 8 (1.1) 0.38 (0.10–1.41) 0.15
Late* 0 (0) 3 (0.4) 0.14 (0.01–2.75) 0.25
Very late* 0 (0) 2 (0.3) 0.20 (0.01–1.16) 0.25
Overall 3 (0.4) 13 (1.8) 0.25 (0.07–0.89) 0.032
Deﬁnite or probable ST
Early 24 (3.4) 38 (5.4) 0.61 (0.36–1.02) 0.06
Late* 0 (0) 3 (0.4) 0.14 (0.01–2.75) 0.25
Very late* 0 (0) 2 (0.3) 0.20 (0.01–1.16) 0.25
Overall 24 (3.4) 43 (6.1) 0.55 (0.33–0.91) 0.02
Deﬁnite, probable, or possible
ST
Early 24 (3.4) 38 (5.4) 0.60 (0.36–1.02) 0.06
Late 13 (1.8) 13 (1.8) 0.92 (0.40–2.08) 0.84
Very late 8 (1.1) 9 (1.3) 0.71 (0.23–2.25) 0.57
Overall 45 (6.4) 60 (8.5) 0.68 (0.46–1.03) 0.07
Values are n (%). *p values are from 2-sided Fisher exact test.SST stent thrombosis; other abbreviations as in Tables 1 and 3.benefit in favor of EES with respect to the primary endpoint
failed to reach conventional levels of statistical significance
among STE-ACS patients, confidence intervals overlapped
widely and formal tests for interaction between type of ACS
and stent type showed no significant difference. These
results are of interest as they may put to rest previous
concerns of late adverse outcomes using DES, particularly
among STE-ACS patients, but certainly require confirma-
tion in large prospective trials confined to STE-ACS
patients, such as the EXAMINATION (A Clinical Eval-
uation of Everolimus Eluting Coronary Stents in the
Treatment of Patients With ST-Segment Elevation Myo-
cardial Infarction; NCT00828087).
Study limitations. The present study was not a randomized
omparison of EES with SES and, therefore, the findings
ay have been subject to bias. However, we attempted to
inimize bias using propensity score matching for a wide
ange of clinical variables. Propensity score was defined as
he probability for a patient to receive EES depending on
he pre-treatment covariates, which summarize what is
nown about that patient before treatment assignment. By
his very definition, it is not possible to include procedural
haracteristics of the compared interventions in the propen-
ity score model because they may explain part of the
reatment effect themselves (20). Yet, procedural character-
stics after propensity score matching were different between
roups. However, we must point out that, if anything, the
igher procedural complexity disadvantaged the EES group.
omposite of death, MI, and TVR in patients treated with EES or SES at
odels. Abbreviations as in Figure 1.the cecond, the sequential enrollment period for patients
e 1.
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152treated with SES and EES may have influenced the results.
It cannot be excluded that changes in overall treatment may
have had a favorable impact on clinical outcome among
more recently included patients. However, results were
obtained at a single institution with similar patient profile
during sequential enrollment periods, thus minimizing the risk
of institutional heterogeneity. Treatment protocols, as well as
medical regimens, including clopidogrel duration, did not
Figure 3. Stent Thrombosis
Cumulative incidence of deﬁnite stent thrombosis (ST) (left) and deﬁnite or pr
lated according to Cox proportional hazards models. Abbreviations as in Figur
Figure 4. Stratified Analysis of the Primary Endpoint
Forest plot summarizing a stratiﬁed analysis for major subgroups with respect
analysis. CI  conﬁdence interval; HR  hazard ratio; LVEF  left ventricular ejectionchange during the enrollment periods. Moreover, the sequen-
tial enrollment of first SES and later EES minimizes the
potential of bias by indication because there was no competi-
tion between the 2 stent types at any point.
The clinical implications of the present study are 2-fold:
First, DES efficacy in ACS patients can be further advanced
beyond the level of the previous gold standard of SES
without compromising, but rather even improving, their
e ST (right) according to stent type through 3 years. p values were calcu-
primary endpoint. The stratiﬁed analysis was performed using unpairedobablto the
fraction; other abbreviations as in Figure 1.
s 1 and
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153safety profile. Second, EES appear to be associated with a
lower propensity for ST as compared with SES among ACS
patients. This finding is of particular importance as it relates
to the late time period (beyond 1 year), because ACS was 1
of the predictors of very late ST with the use of early-
generation DES. The latter may have important implica-
tions for the duration of dual antiplatelet therapy.
Conclusions
Among patients with ACS, the unrestricted use of EES is
associated with improved clinical outcome compared with
SES during long-term follow-up to 3 years. Notably, the
risk of ST was lower among EES-treated ACS patients
during long-term follow-up.
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